

Dina Sigano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1192156/publications.pdf>

Version: 2024-02-01

232
papers

11,357
citations

26610

56
h-index

36008

97
g-index

262
all docs

262
docs citations

262
times ranked

8511
citing authors

#	ARTICLE	IF	CITATIONS
1	Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain. <i>Cancer Biology and Therapy</i> , 2020, 21, 223-230.	1.5	10
2	Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses. <i>Cell Reports</i> , 2017, 21, 1169-1179.	2.9	57
3	Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 190-197.	1.4	44
4	The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. <i>Biochemical Pharmacology</i> , 2015, 93, 389-400.	2.0	34
5	PABA/NO lead optimization: Improved targeting of cytotoxicity to glutathione S-transferase P1-overexpressing cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 4980-4988.	1.4	7
6	Assay Reproducibility and Interindividual Variation for 15 Serum Estrogens and Estrogen Metabolites Measured by Liquid Chromatography-Tandem Mass Spectrometry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2649-2657.	1.1	27
7	Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells. <i>Leukemia Research</i> , 2014, 38, 377-382.	0.4	14
8	Nitric Oxide (NO) Releasing Poly ADP-ribose Polymerase 1 (PARP-1) Inhibitors Targeted to Glutathione S-Transferase P1-Overexpressing Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2292-2302.	2.9	36
9	Aminolysis of an N-Diazeniumdiolated Amidine as an Approach to Diazeniumdiolated Ammonia. <i>Journal of Organic Chemistry</i> , 2014, 79, 4512-4516.	1.7	0
10	Diacylglycerol Lactones Targeting the Structural Features That Distinguish the Atypical C1 Domains of Protein Kinase C α and β from Typical C1 Domains. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 3835-3844.	2.9	4
11	Analysis of the HNO and NO donating properties of alicyclic amine diazeniumdiolates. <i>Nitric Oxide - Biology and Chemistry</i> , 2014, 42, 70-78.	1.2	22
12	Direct Reaction of Amides with Nitric Oxide To Form Diazeniumdiolates. <i>Journal of Organic Chemistry</i> , 2014, 79, 9389-9393.	1.7	20
13	Stereochemical Origins of Chromophore Extension in O ₂ -Substituted Diazeniumdiolates, Prodrugs of Nitric Oxide. <i>Journal of Chemical Crystallography</i> , 2013, 43, 123-126.	0.5	0
14	Decoding Nitric Oxide Release Rates of Amine-Based Diazeniumdiolates. <i>Journal of Physical Chemistry A</i> , 2013, 117, 6671-6677.	1.1	6
15	Green tea intake is associated with urinary estrogen profiles in Japanese-American women. <i>Nutrition Journal</i> , 2013, 12, 25.	1.5	23
16	Enzymatic generation of the NO/HNO-releasing IPA/NO anion at controlled rates in physiological media using β -galactosidase. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 35, 131-136.	1.2	14
17	Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI. <i>Nitric Oxide - Biology and Chemistry</i> , 2013, 30, 17-25.	1.2	18
18	Abstract 3334: GSTP1-activated nitric oxide-releasing/PARP inhibitor hybrid prodrugs induce cancer cell death through ROS/RNS, DNA damage, ER stress, and apoptosis.., 2013, , .		0

#	ARTICLE	IF	CITATIONS
19	JS-K, a Glutathione S-Transferase-Activated Nitric Oxide Donor With Antineoplastic Activity in Malignant Gliomas. <i>Neurosurgery</i> , 2012, 70, 497-510.	0.6	42
20	Molecular Basis for Failure of Atypical C1 Domain of Vav1 to Bind Diacylglycerol/Phorbol Ester. <i>Journal of Biological Chemistry</i> , 2012, 287, 13137-13158.	1.6	15
21	Urinary Estrogens and Estrogen Metabolites and Subsequent Risk of Breast Cancer among Premenopausal Women. <i>Cancer Research</i> , 2012, 72, 696-706.	0.4	83
22	Estrogen Metabolism and Risk of Breast Cancer in Postmenopausal Women. <i>Journal of the National Cancer Institute</i> , 2012, 104, 326-339.	3.0	174
23	O ² -Functionalized Methylamine Diazeniumdiolates: Evidence for E ₂ , Z ₂ Equilibration in an Acyclic System. <i>Journal of Organic Chemistry</i> , 2012, 77, 10804-10810.	1.7	9
24	Cross-Linking Protein Glutathionylation Mediated by O ₂ -Arylated Bis-Diazeniumdiolate -Double JS-K- Chemical Research in Toxicology, 2012, 25, 2670-2677.	1.7	5
25	Nitrous oxide as a primary product in base-mediated \hat{I}^2 -elimination reactions of diazeniumdiolated benzylamine derivatives. <i>Chemical Communications</i> , 2012, 48, 5931.	2.2	1
26	Richard Loeppky (1937-2012). <i>Chemical Research in Toxicology</i> , 2012, 25, 1155-1156.	1.7	0
27	The Role of Estrogen Receptor \hat{I}^{\pm} and \hat{I}^2 in Regulating Vascular Smooth Muscle Cell Proliferation is Based on Sex. <i>Journal of Surgical Research</i> , 2012, 173, e1-e10.	0.8	23
28	Diazeniumdiolated carbamates: A novel class of nitric oxide donors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 2025-2029.	1.4	31
29	Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3094-3099.	1.4	14
30	Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-activated nitric oxide donor PABA/NO in malignant gliomas. <i>International Journal of Cancer</i> , 2012, 130, 1184-1194.	2.3	44
31	Novel protection-deprotection strategies in diazeniumdiolate chemistry: synthesis of V-IPA/NO. <i>Chemical Communications</i> , 2011, 47, 6710.	2.2	16
32	Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7751-7758.	2.9	22
33	HNO and NO Release from a Primary Amine-Based Diazeniumdiolate As a Function of pH. <i>Inorganic Chemistry</i> , 2011, 50, 3262-3270.	1.9	67
34	Fifty Years of Diazeniumdiolate Research. From Laboratory Curiosity to Broad-Spectrum Biomedical Advances. <i>ACS Chemical Biology</i> , 2011, 6, 1147-1155.	1.6	161
35	Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia. <i>Nitric Oxide - Biology and Chemistry</i> , 2011, 25, 22-30.	1.2	23
36	JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells. <i>International Journal of Oncology</i> , 2011, 38, 963-71.	1.4	26

#	ARTICLE	IF	CITATIONS
37	Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status. <i>Free Radical Biology and Medicine</i> , 2011, 50, 1065-1074.	1.3	22
38	Nitric oxide donor, V-PROLI/NO, provides protection against arsenical induced toxicity in rat liver cells: Requirement for Cyp1a1. <i>Chemico-Biological Interactions</i> , 2011, 193, 88-96.	1.7	4
39	Nitric Oxide Inhibits Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia by Increasing the Ubiquitination and Degradation of UbcH10. <i>Cell Biochemistry and Biophysics</i> , 2011, 60, 89-97.	0.9	67
40	Poly(diol-co-citrate)s as Novel Elastomeric Perivascular Wraps for the Reduction of Neointimal Hyperplasia. <i>Macromolecular Bioscience</i> , 2011, 11, 700-709.	2.1	29
41	N-Methyl-Substituted Fluorescent DAG-Indololactone Isomers Exhibit Dramatic Differences in Membrane Interactions and Biological Activity. <i>ChemBioChem</i> , 2011, 12, 2331-2340.	1.3	9
42	Materials from peptide assembly: towards the treatment of cancer and transmittable disease. <i>Current Opinion in Chemical Biology</i> , 2011, 15, 427-434.	2.8	75
43	Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas. <i>Neuro-Oncology</i> , 2011, 13, 203-211.	0.6	33
44	The Nitric Oxide Prodrug JS-K Is Effective against Non-Small-Cell Lung Cancer Cells In Vitro and In Vivo: Involvement of Reactive Oxygen Species. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 336, 313-320.	1.3	64
45	JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 62, 145-151.	1.2	31
46	JS-K; a nitric oxide-releasing prodrug, modulates β -catenin/TCF signaling in leukemic Jurkat cells: Evidence of an S-nitrosylated mechanism. <i>Biochemical Pharmacology</i> , 2010, 80, 1641-1649.	2.0	35
47	Membrane-Surface Anchoring of Charged Diacylglycerol-Lactones Correlates with Biological Activities. <i>ChemBioChem</i> , 2010, 11, 2003-2009.	1.3	2
48	Inside Cover: Membrane-Surface Anchoring of Charged Diacylglycerol-Lactones Correlates with Biological Activities (ChemBioChem 14/2010). <i>ChemBioChem</i> , 2010, 11, 1926-1926.	1.3	0
49	Stability of 15 Estrogens and Estrogen Metabolites in Urine Samples under Processing and Storage Conditions Typically Used in Epidemiologic Studies. <i>International Journal of Biological Markers</i> , 2010, 25, 185-194.	0.7	16
50	Comparison of Liquid Chromatography-Tandem Mass Spectrometry, RIA, and ELISA Methods for Measurement of Urinary Estrogens. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 292-300.	1.1	84
51	Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O ² -(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazonium-1,2-diolate (NONO-ASA) as Safe Anti-Inflammatory, Analgesic, Antipyretic, Antioxidant Prodrugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 443-450.	1.3	30
52	Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. <i>Journal of Experimental Medicine</i> , 2010, 207, 2455-2467.	4.2	86
53	Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 299, H772-H779.	1.5	17
54	Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. <i>Journal of Vascular Surgery</i> , 2010, 51, 1248-1259.	0.6	52

#	ARTICLE	IF	CITATIONS
55	â€œClickâ€•Reaction in Conjunction with Diazeniumdiolate Chemistry: Developing High-Load Nitric Oxide Donors. <i>Organic Letters</i> , 2010, 12, 4256-4259.	2.4	23
56	Dual Mechanisms of HNO Generation by a Nitroxyl Prodrug of the Diazeniumdiolate (NONOate) Class. <i>Journal of the American Chemical Society</i> , 2010, 132, 16526-16532.	6.6	52
57	The Nitric Oxide Prodrug V-PROLI/NO Inhibits Cellular Uptake of Proline. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 386-389.	1.3	7
58	Glycosylated PROLI/NO Derivatives as Nitric Oxide Prodrugs. <i>Organic Letters</i> , 2010, 12, 56-59.	2.4	9
59	Stabilization of the Nitric Oxide (NO) Prodrugs and Anticancer Leads, PABA/NO and Double JS-K, through Incorporation into PEG-Protected Nanoparticles. <i>Molecular Pharmaceutics</i> , 2010, 7, 291-298.	2.3	84
60	Tailored synthesis of nitric oxide-releasing polyurethanes using O ₂ -protected diazeniumdiolated chain extenders. <i>Journal of Materials Chemistry</i> , 2010, 20, 3107.	6.7	26
61	Arylation of Sensitive 1-(Pyrrolidin-1-yl)-diazene-1-ium-diolate in Ionic Liquids. <i>Synthetic Communications</i> , 2010, 40, 1322-1332.	1.1	3
62	Nitrogen-bound diazeniumdiolated amidines. <i>Chemical Communications</i> , 2010, 46, 5799.	2.2	5
63	Unexpected Incorporation of Bromine at a Non-anomeric Position during the Synthesis of an O ₂ -Glycosylated Diazeniumdiolate. <i>Organic Preparations and Procedures International</i> , 2009, 41, 143-147.	0.6	1
64	Soy Intake is Associated with Increased 2-Hydroxylation and Decreased 16 α -Hydroxylation of Estrogens in Asian-American Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2751-2760.	1.1	19
65	Northâ€•and Southâ€•Bicyclo[3.1.0]Hexene Nucleosides: The Effect of Ring Planarity on Antiâ€•HIV Activity. <i>ChemMedChem</i> , 2009, 4, 1354-1363.	1.6	5
66	Vâ€•PROLI/NO, a nitric oxide donor prodrug, protects liver cells from arsenicâ€•induced toxicity. <i>Cancer Science</i> , 2009, 100, 382-388.	1.7	11
67	Improved synthesis of V-PYRRO/NO, a liver-selective nitric oxide prodrug, and analogues. <i>Tetrahedron Letters</i> , 2009, 50, 2069-2071.	0.7	8
68	An improved synthesis of V-PROLI/NO, a cytochrome P450-activated nitric oxide prodrug. <i>Tetrahedron Letters</i> , 2009, 50, 4545-4548.	0.7	3
69	Primary amine diazeniumdiolate ions of structure {RNN(O)NOR ² } ⁺ as ambident nucleophiles. <i>Tetrahedron Letters</i> , 2009, 50, 5917-5919.	0.7	3
70	JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C). <i>Leukemia Research</i> , 2009, 33, 1525-1529.	0.4	30
71	Ceramides: Branched alkyl chains in the sphingolipid siblings of diacylglycerol improve biological potency. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1498-1505.	1.4	8
72	Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2760-2762.	1.0	16

#	ARTICLE	IF	CITATIONS
73	Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells. <i>Genomics</i> , 2009, 94, 32-38.	1.3	13
74	Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 2657-2664.	1.4	29
75	Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9764-9771.	1.4	46
76	Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 950-953.	1.0	23
77	Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. <i>Free Radical Biology and Medicine</i> , 2008, 44, 73-81.	1.3	67
78	Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia. <i>Journal of Vascular Surgery</i> , 2008, 47, 173-182.	0.6	122
79	TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. <i>Breast Cancer Research</i> , 2008, 10, R44.	2.2	54
80	Hydrolytic Reactivity Trends among Potential Prodrugs of the O ² -Glycosylated Diazeniumdiolate Family. Targeting Nitric Oxide to Macrophages for Antileishmanial Activity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3961-3970.	2.9	40
81	Nitric Oxide Reacts with Methoxide. <i>Journal of Organic Chemistry</i> , 2008, 73, 1139-1142.	1.7	17
82	Aryl Bis(diazeniumdiolates): Potent Inducers of S-Glutathionylation of Cellular Proteins and Their in Vitro Antiproliferative Activities. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7944-7952.	2.9	20
83	Conformationally Constrained Analogues of Diacylglycerol. 29. Cells Sort Diacylglycerol-Lactone Chemical Zip Codes to Produce Diverse and Selective Biological Activities. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5198-5220.	2.9	40
84	Cell-Permeable Esters of Diazeniumdiolate-Based Nitric Oxide Prodrugs. <i>Organic Letters</i> , 2008, 10, 5155-5158.	2.4	23
85	Second-Generation Aspirin and Indomethacin Prodrugs Possessing an O ² -(Acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate Nitric Oxide Donor Moiety: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 1954-1961.	2.9	61
86	Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H2388-H2398.	1.5	31
87	The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis. <i>Cancer Letters</i> , 2007, 256, 238-245.	3.2	9
88	Quantitative Measurement of Endogenous Estrogens and Estrogen Metabolites in Human Serum by Liquid Chromatography-Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2007, 79, 7813-7821.	3.2	233
89	Conformationally Constrained Analogues of Diacylglycerol (DAG). 28. DAG-dioxolanones Reveal a New Additional Interaction Site in the C1b Domain of PKC β . <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3465-3481.	2.9	11
90	V-PROLI/NO, a Prodrug of the Nitric Oxide Donor, PROLI/NO. <i>Organic Letters</i> , 2007, 9, 3409-3412.	2.4	32

#	ARTICLE	IF	CITATIONS
91	Nitric Oxide-Releasing Fabrics and Other Acrylonitrile-Based Diazeniumdiolates. <i>Journal of the American Chemical Society</i> , 2007, 129, 3786-3787.	6.6	46
92	Nitric Oxide Prodrugs: Diazeniumdiolate Anions of Hindered Secondary Amines. <i>Organic Letters</i> , 2007, 9, 4551-4554.	2.4	24
93	Conformationally Constrained Analogues of Diacylglycerol (DAG). 27. Modulation of Membrane Translocation of Protein Kinase C (PKC) Isozymes I β and I γ by Diacylglycerol Lactones (DAG-lactones) Containing Rigid-Rod Acyl Groups. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 962-978.	2.9	20
94	O ₂ -Acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO $\hat{=}$ NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 4767-4774.	1.4	70
95	A liquid chromatography $\hat{=}$ mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. <i>Nature Protocols</i> , 2007, 2, 1350-1355.	5.5	72
96	Nitric Oxide Releasing Polyurethanes with Covalently Linked Diazeniumdiolated Secondary Amines. <i>Biomacromolecules</i> , 2006, 7, 987-994.	2.6	83
97	Antitumor Activity of JS-K [O ₂ -(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O ₂ -Aryl Diazeniumdiolates in Vitro and in Vivo. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 4356-4366.	2.9	102
98	PABA/NO as an Anticancer Lead: Analogue Synthesis, Structure Revision, Solution Chemistry, Reactivity toward Glutathione, and in Vitro Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 1157-1164.	2.9	85
99	Conformationally Constrained Analogues of Diacylglycerol. 26. Exploring the Chemical Space Surrounding the C1 Domain of Protein Kinase C with DAG-Lactones Containing Aryl Groups at the sn-1 and sn-2 Positions. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3185-3203.	2.9	12
100	Deamidation of peptides in aerobic nitric oxide solution by a nitrosative pathway. <i>Nitric Oxide - Biology and Chemistry</i> , 2006, 14, 144-151.	1.2	7
101	Metabolism of a liver-selective nitric oxide-releasing agent, V-PYRRO/NO, by human microsomal cytochromes P450. <i>Nitric Oxide - Biology and Chemistry</i> , 2006, 14, 309-315.	1.2	15
102	Injectable formulation of disodium 1-[2-(carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO), an ultrafast nitric oxide donor prodrug. <i>Journal of Pharmaceutical Sciences</i> , 2006, 95, 108-115.	1.6	14
103	A Glutathione S-Transferase $\hat{=}$ Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins. <i>Molecular Pharmacology</i> , 2006, 69, 501-508.	1.0	104
104	Nitric Oxide (NO)- and Nitroxyl (HNO)-Generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 625-636.	1.0	121
105	Comparison of the NO and HNO Donating Properties of Diazeniumdiolates: Primary Amine Adducts Release HNO in Vivo. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 8220-8228.	2.9	118
106	Measuring Fifteen Endogenous Estrogens Simultaneously in Human Urine by High-Performance Liquid Chromatography-Mass Spectrometry. <i>Analytical Chemistry</i> , 2005, 77, 6646-6654.	3.2	206
107	Chemistry of the Diazeniumdiolates: Isomerism. <i>Journal of the American Chemical Society</i> , 2005, 127, 5388-5395.	6.6	16
108	Diazeniumdiolate Ions as Leaving Groups in Anomeric Displacement Reactions: A Protection $\hat{=}$ Deprotection Strategy for Ionic Diazeniumdiolates. <i>Journal of the American Chemical Society</i> , 2005, 127, 14188-14189.	6.6	27

#	ARTICLE	IF	CITATIONS
109	Carbon-Bound Diazeniumdiolates from the Reaction of Nitric Oxide with Amidines. <i>Journal of Organic Chemistry</i> , 2005, 70, 7647-7653.	1.7	11
110	The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level. <i>Nitric Oxide - Biology and Chemistry</i> , 2005, 12, 114-120.	1.2	22
111	JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells.. <i>Blood</i> , 2005, 106, 1593-1593.	0.6	0
112	Tumor Cell Responses to a Novel Glutathione S-Transferase-Activated Nitric Oxide-Releasing Prodrug. <i>Molecular Pharmacology</i> , 2004, 65, 1070-1079.	1.0	115
113	Chemistry of the Diazeniumdiolates. O- versus N-Alkylation of the RNH[N(O)NO]-Ion. <i>Journal of the American Chemical Society</i> , 2004, 126, 12880-12887.	6.6	33
114	Conformationally Constrained Analogues of Diacylglycerol. 20. The Search for an Elusive Binding Site on Protein Kinase C through Relocation of the Carbonyl Pharmacophore Along the sn-1 Side Chain of 1,2-Diacylglycerol Lactones. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 644-655.	2.9	15
115	Conformationally Constrained Analogues of Diacylglycerol. 24. Asymmetric Synthesis of a Chiral (R)-DAG-Lactone Template as a Versatile Precursor for Highly Functionalized DAG-Lactones. <i>Organic Letters</i> , 2004, 6, 2413-2416.	2.4	31
116	Conformationally Constrained Analogues of Diacylglycerol. 21. A Solid-Phase Method of Synthesis of Diacylglycerol Lactones as a Prelude to a Combinatorial Approach for the Synthesis of Protein Kinase C Isozyme-Specific Ligands. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3248-3254.	2.9	15
117	Conformationally Constrained Analogues of Diacylglycerol (DAG). 23. Hydrophobic Ligand-Protein Interactions versus Ligand-Lipid Interactions of DAG-Lactones with Protein Kinase C (PK-C). <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4858-4864.	2.9	11
118	Measuring Seven Endogenous Ketolic Estrogens Simultaneously in Human Urine by High-Performance Liquid Chromatography-Mass Spectrometry. <i>Analytical Chemistry</i> , 2004, 76, 5829-5836.	3.2	31
119	JS-K, a Novel Nitric Oxide (NO) Generator, Induces Cytochrome c Release and Caspase Activation in HL-60 Myeloid Leukemia Cells.. <i>Blood</i> , 2004, 104, 3415-3415.	0.6	1
120	The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. <i>Hepatology</i> , 2003, 37, 324-333.	3.6	78
121	The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced nephrotoxicity in mice. <i>Toxicology</i> , 2003, 189, 173-180.	2.0	48
122	Differential Binding Modes of Diacylglycerol (DAG) and DAG Lactones to Protein Kinase C (PK-C). <i>Journal of Medicinal Chemistry</i> , 2003, 46, 1571-1579.	2.9	32
123	Preparation and Reactivity of O ₂ -Sulfonated Diazeniumdiolates. <i>Journal of Organic Chemistry</i> , 2003, 68, 656-657.	1.7	4
124	Thwarting thrombus. <i>Nature Materials</i> , 2003, 2, 357-358.	13.3	70
125	Rational Design of Drugs That Induce Human Immunodeficiency Virus Replication. <i>Journal of Virology</i> , 2003, 77, 10227-10236.	1.5	44
126	PROGRESS TOWARD CLINICAL APPLICATION OF THE NITRIC OXIDE-RELEASING DIAZENIUMDIOLATES. <i>Annual Review of Pharmacology and Toxicology</i> , 2003, 43, 585-607.	4.2	187

#	ARTICLE	IF	CITATIONS
127	Selective opening of the blood-brain barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas. <i>Journal of Neurosurgery</i> , 2003, 99, 728-737.	0.9	45
128	O ² -Vinyl 1-(Pyrrolidin-1-yl)diazen-1-ium-1,2-diolate Protection Against d-Galactosamine/Endotoxin-Induced Hepatotoxicity in Mice: Genomic Analysis Using Microarrays. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 18-25.	1.3	51
129	Augmentation of Intrapericardial Nitric Oxide Level by a Prolonged-Release Nitric Oxide Donor Reduces Luminal Narrowing After Porcine Coronary Angioplasty. <i>Circulation</i> , 2002, 105, 2779-2784.	1.6	63
130	A Nitric Oxide-Releasing Polydiazoniumdiolate Derived from Acetonitrile. <i>Organic Letters</i> , 2002, 4, 1323-1325.	2.4	15
131	Chemistry of the Nitric Oxide-Releasing Diazoniumdiolate (Nitrosohydroxylamine) Functional Group and Its Oxygen-Substituted Derivatives. <i>Chemical Reviews</i> , 2002, 102, 1135-1154.	23.0	428
132	Mechanistic insight into exclusive nitric oxide recovery from a carbon-bound diazeniumdiolate. <i>Nitric Oxide - Biology and Chemistry</i> , 2002, 7, 103-108.	1.2	7
133	Qualitative Thin-Layer and High-Performance Liquid Chromatographic Analysis of 1-Substituted Diazen-1-ium-1,2-diolates on Aminopropyl-Bonded Silica Gel. <i>Analytical Biochemistry</i> , 2002, 301, 97-102.	1.1	0
134	Stable isotope dilution high-performance liquid chromatography-electrospray ionization mass spectrometry method for endogenous 2- and 4-hydroxyestrogens in human urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 780, 315-330.	1.2	28
135	Nitric oxide induces metallothionein (MT) gene expression apparently by displacing zinc bound to MT. <i>Toxicology Letters</i> , 2001, 119, 103-108.	0.4	49
136	The Secondary Amine/Nitric Oxide Complex Ion R ₂ N[N(O)NO] ⁻ as Nucleophile and Leaving Group in S _N Ar Reactions. <i>Journal of Organic Chemistry</i> , 2001, 66, 3090-3098.	1.7	96
137	Chemistry of the Diazoniumdiolates. 2. Kinetics and Mechanism of Dissociation to Nitric Oxide in Aqueous Solution. <i>Journal of the American Chemical Society</i> , 2001, 123, 5473-5481.	6.6	199
138	Pathophysiology of a Sickle Cell Trait Mouse Model: Human β -Globin Transgenes with One Mouse β -Globin Allele. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 971-977.	0.6	24
139	Chemistry of the Diazoniumdiolates I. Structural and Spectral Characteristics of the [N(O)NO] ⁻ Functional Group. <i>Nitric Oxide - Biology and Chemistry</i> , 2001, 5, 377-394.	1.2	82
140	An Optimized Protein Kinase C Activating Diacylglycerol Combining High Binding Affinity (K _i) with Reduced Lipophilicity (log P). <i>Journal of Medicinal Chemistry</i> , 2001, 44, 1892-1904.	2.9	26
141	V-PYRRO/NO: AN HEPATO-SELECTIVE NITRIC OXIDE DONOR IMPROVES PORCINE LIVER HEMODYNAMICS AND FUNCTION AFTER ISCHEMIA REPERFUSION ¹ . <i>Transplantation</i> , 2001, 71, 193-198.	0.5	42
142	Analysis of Vasodilator Responses to Novel Nitric Oxide Donors in the Hindquarters Vascular Bed of the Cat. <i>Journal of Cardiovascular Pharmacology</i> , 2001, 38, 120-129.	0.8	12
143	l-Tyrosine and nitric oxide synergize to prevent cytotoxic effects of superoxide. <i>Toxicology</i> , 2001, 165, 163-170.	2.0	3
144	Chemistry of the Diazoniumdiolates. 3. Photoreactivity. <i>Journal of the American Chemical Society</i> , 2001, 123, 5465-5472.	6.6	62

#	ARTICLE	IF	CITATIONS
145	Comparison of responses to novel nitric oxide donors in the feline pulmonary vascular bed. <i>European Journal of Pharmacology</i> , 2001, 430, 311-315.	1.7	29
146	Inhibition of Oxidized Low-density Lipoprotein-induced Apoptosis in Endothelial Cells by Nitric Oxide. <i>Journal of Biological Chemistry</i> , 2001, 276, 17316-17323.	1.6	59
147	Overexpression of Glutathione S-Transferase II and Multidrug Resistance Transport Proteins Is Associated with Acquired Tolerance to Inorganic Arsenic. <i>Molecular Pharmacology</i> , 2001, 60, 302-309.	1.0	219
148	Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. <i>Biomaterials</i> , 2000, 21, 9-21.	5.7	205
149	Reaction of nitric oxide with benzyl cyanide to yield a bis-diazeniumdiolated imidate. <i>Tetrahedron Letters</i> , 2000, 41, 8421-8424.	0.7	19
150	Diazeniumdiolates. <i>Free Radical Biology and Medicine</i> , 2000, 28, 1463-1469.	1.3	124
151	Induction of Proliferative Lesions of the Uterus, Testes, and Liver in Swiss Mice Given Repeated Injections of Sodium Arsenate: Possible Estrogenic Mode of Action. <i>Toxicology and Applied Pharmacology</i> , 2000, 166, 24-35.	1.3	105
152	Conversion of a polysaccharide to nitric oxide-releasing form. dual-mechanism anticoagulant activity of diazeniumdiolated heparin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 751-753.	1.0	21
153	Esterase-Sensitive Nitric Oxide Donors of the Diazeniumdiolate Family: In Vitro Antileukemic Activity. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 261-269.	2.9	121
154	Reaction of Nitric Oxide at the β^2 -Carbon of Enamines. A New Method of Preparing Compounds Containing the Diazeniumdiolate Functional Group. <i>Journal of Organic Chemistry</i> , 2000, 65, 5745-5751.	1.7	30
155	ADDUCTS OF PIPERAZINE WITH NITRIC OXIDE. <i>Organic Preparations and Procedures International</i> , 1999, 31, 189-192.	0.6	10
156	Pharmacokinetics and consistency of pericardial delivery directed to coronary arteries: Direct comparison with endoluminal delivery. <i>Clinical Cardiology</i> , 1999, 22, 10-16.	0.7	34
157	INDUCTION OF PENILE ERECTION BY INTRACAVERNOSAL AND TRANSURETHRAL ADMINISTRATION OF NOVEL NITRIC OXIDE DONORS IN THE CAT. <i>Journal of Urology</i> , 1999, 161, 2013-2019.	0.2	22
158	Piperazine as a Linker for Incorporating the Nitric Oxide-Releasing Diazeniumdiolate Group into Other Biomedically Relevant Functional Molecules. <i>Journal of Organic Chemistry</i> , 1999, 64, 5124-5131.	1.7	57
159	Conversion of Proteins to Diazeniumdiolate-Based Nitric Oxide Donors. <i>Bioconjugate Chemistry</i> , 1999, 10, 838-842.	1.8	26
160	Reaction of nitric oxide with the imine double bond of certain Schiff bases. <i>Tetrahedron Letters</i> , 1998, 39, 5933-5936.	0.7	23
161	N-Nitrosated N-hydroxyguanidines are nitric oxide-releasing diazeniumdiolates. <i>Chemical Communications</i> , 1998, , 1191-1192.	2.2	12
162	Involvement of K ⁺ ATP Channels in Nitric Oxide-Induced Inhibition of Spontaneous Contractile Activity of the Nonpregnant Human Myometrium. <i>Biochemical and Biophysical Research Communications</i> , 1998, 253, 653-657.	1.0	22

#	ARTICLE	IF	CITATIONS
163	Targeting Nitric Oxide (NO) Delivery in Vivo. Design of a Liver-Selective NO Donor Prodrug That Blocks Tumor Necrosis Factor- α -Induced Apoptosis and Toxicity in the Liver. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 1947-1954.	2.9	268
164	Boundary Layer Infusion of Nitric Oxide Reduces Early Smooth Muscle Cell Proliferation in the Endarterectomized Canine Artery. <i>Journal of Surgical Research</i> , 1997, 67, 26-32.	0.8	33
165	Quantification of Diazeniumdiolate Mutagenicity in Four Different <i>In Vitro</i> Assays. <i>Nitric Oxide - Biology and Chemistry</i> , 1997, 1, 158-166.	1.2	3
166	Differential Effects of Nonselective Nitric Oxide Synthase (NOS) and Selective Inducible NOS Inhibition on Hepatic Necrosis, Apoptosis, ICAM-1 Expression, and Neutrophil Accumulation during Endotoxemia. <i>Nitric Oxide - Biology and Chemistry</i> , 1997, 1, 404-416.	1.2	117
167	An Evaluation of the Roles of Metabolic Denitrosation and α -Hydroxylation in the Hepatotoxicity of N-Nitrosodimethylamine. <i>Chemical Research in Toxicology</i> , 1996, 9, 1319-1324.	1.7	30
168	Localizing Antithrombotic and Vasodilatory Activity with a Novel, Ultrafast Nitric Oxide Donor. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 4361-4365.	2.9	144
169	Deamination of Single-Stranded DNA Cytosine Residues in Aerobic Nitric Oxide Solution at Micromolar Total NO Exposures. <i>Chemical Research in Toxicology</i> , 1996, 9, 891-896.	1.7	30
170	Nitric Oxide-Releasing Polymers Containing the [N(O)NO]-Group. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1148-1156.	2.9	205
171	Synthesis of Cyclopropylpyrrolidines via Reaction of <i>n</i> -Allyl-N-propargylamides with a Molybdenum Carbene Complex. Effect of Substituents and Reaction Conditions. <i>Journal of Organic Chemistry</i> , 1996, 61, 2268-2272.	1.7	85
172	Carbene-alkyne-alkene Cyclization Reactions. <i>Chemical Reviews</i> , 1996, 96, 271-288.	23.0	254
173	Histogenesis and the role of p53 and K-ras mutations in hepatocarcinogenesis by glyceryl trinitrate (nitroglycerin) in male F344 rats. <i>Carcinogenesis</i> , 1996, 17, 2477-2486.	1.3	28
174	Nitric Oxide (NO) Donor Molecules. <i>Journal of Cardiovascular Pharmacology</i> , 1995, 25, 674-678.	0.8	213
175	Nitric oxide and ethylnitrosourea: relative mutagenicity in the p53 tumor suppressor and hypoxanthine-phosphoribosyltransferase genes. <i>Carcinogenesis</i> , 1995, 16, 2069-2074.	1.3	41
176	Diethylamine/Nitric Oxide (NO) Adduct, an NO Donor, Produces Potent Pulmonary and Systemic Vasodilation in Intact Newborn Lambs. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 23, 113-119.	0.8	34
177	Nitrite-induced mutations in a forward mutation assay: Influence of nitrite concentration and pH. <i>Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure</i> , 1994, 322, 341-346.	1.2	27
178	Preparation of Osmium Hydrazido Complexes by Interception of an Osmium(IV) Imido Intermediate. <i>Journal of the American Chemical Society</i> , 1994, 116, 3649-3650.	6.6	31
179	DNA Sequence Changes Induced by Two Nitric Oxide Donor Drugs in the supF Assay. <i>Chemical Research in Toxicology</i> , 1994, 7, 628-632.	1.7	90
180	New nitric oxide-releasing zwitterions derived from polyamines. <i>Journal of Organic Chemistry</i> , 1993, 58, 1472-1476.	1.7	594

#	ARTICLE	IF	CITATIONS
181	An unusual binuclear sandwich complex formed in the reaction of CuCl ₂ with the Et ₂ N ⁺ N ₂ O ₂ ⁻ ion. Journal of the Chemical Society Chemical Communications, 1993, , 937-939.	2.0	20
182	Hepatic cytochrome P450 2B-type induction by ethyl/phenyl-substituted congeners of phenobarbital in the rat. Chemical Research in Toxicology, 1993, 6, 180-187.	1.7	12
183	Mutagenicity of glyceryl trinitrate (nitroglycerin) in Salmonella typhimurium. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1993, 298, 187-195.	1.2	33
184	Mutations induced by saturated aqueous nitric oxide in the pSP189 supF gene in human Ad293 and E. coli MBM7070 cells. Carcinogenesis, 1993, 14, 1251-1254.	1.3	107
185	Nitric Oxide/Nucleophile Complexes. Journal of Cardiovascular Pharmacology, 1993, 22, S3-9.	0.8	28
186	Complexes of Nitric Oxide with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide. Journal of Cardiovascular Pharmacology, 1993, 22, 287-292.	0.8	77
187	Mechanism of Vascular Relaxation Induced by the Nitric Oxide (NO)/Nucleophile Complexes, a New Class of NO-Based Vasodilators. Journal of Cardiovascular Pharmacology, 1993, 21, 670-676.	0.8	72
188	Ion-Pairing Systems for Separation of <i>N</i> -Nitrosodimethylamine and its Metabolites in Reversed-Phase High-Performance Liquid Chromatography. Journal of Liquid Chromatography and Related Technologies, 1992, 15, 195-206.	0.9	3
189	Secondary amine/nitric oxide complex ions, R ₂ N[N(O)NO] ⁻ . O-Functionalization chemistry. Journal of Organic Chemistry, 1992, 57, 6134-6138.	1.7	85
190	Mixed ligand, non-nitrosyl Cu(II) complexes as potential cardiovascular agents via no release.. Journal of Inorganic Biochemistry, 1992, 47, 47.	1.5	0
191	A kinetic investigation of intermediates formed during the Fenton reagent mediated degradation of N-nitrosodimethylamine: evidence for an oxidative pathway not involving hydroxyl radical. Chemical Research in Toxicology, 1991, 4, 510-512.	1.7	54
192	Complexes of .NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. Journal of Medicinal Chemistry, 1991, 34, 3242-3247.	2.9	730
193	² H-Deuteration of N-nitrosoethylmethylamine causes a shift in DNA methylation from rat liver to esophagus. Carcinogenesis, 1991, 12, 545-549.	1.3	4
194	Single-dose toxicokinetics of N-nitrosomethylethylamine and N-nitrosomethyl (2,2,2-trideuterioethyl)amine in the rat. Archives of Toxicology, 1990, 64, 109-115.	1.9	3
195	Determination of 3-methyl-4,5-dihydro-1,2,3-oxadiazolium ion, a putative nitrosamine metabolite, by ion-pair chromatography with electrochemical detection. Analytica Chimica Acta, 1990, 232, 397-400.	2.6	0
196	Stereoselectivity in the microsomal conversion of N-nitrosodimethylamine to formaldehyde. Chemical Research in Toxicology, 1990, 3, 540-544.	1.7	5
197	Preparation of 2'-deoxyxanthosine by nitrosative deamination of 2'-deoxyguanosine under alkaline aqueous conditions. Tetrahedron Letters, 1989, 30, 1467-1468.	0.7	15
198	The Fenton degradation as a nonenzymic model for microsomal denitrosation of N-nitrosodimethylamine. Chemical Research in Toxicology, 1989, 2, 247-253.	1.7	32

#	ARTICLE	IF	CITATIONS
199	Decomposition and quality control considerations in biological work with fecapentaene preparations. <i>Chemical Research in Toxicology</i> , 1989, 2, 162-168.	1.7	6
200	Nickel-aluminum alloy as a reducing agent. <i>Chemical Reviews</i> , 1989, 89, 459-502.	23.0	68
201	Isolation of stable 1:1 and 2:1 salts of nitrosamines with protic acids. <i>Journal of Organic Chemistry</i> , 1989, 54, 2432-2436.	1.7	7
202	Displacement of O- N-substituents from nitrosamine-derived diazenium ions by three divergent mechanisms. <i>Tetrahedron Letters</i> , 1988, 29, 2903-2906.	0.7	12
203	A symmetrically hydrogen-bonded binitrosamine cation produced on protonation of N-nitrosopyrrolidine. <i>Journal of the American Chemical Society</i> , 1988, 110, 3701-3702.	6.6	10
204	Nitrogen protonation of N-nitrosodimethylamine. <i>Journal of the American Chemical Society</i> , 1988, 110, 7459-7462.	6.6	20
205	Formation of complexed nitrosamines by oxidation of coordinated ammonia in the presence of secondary amines. <i>Journal of the American Chemical Society</i> , 1988, 110, 6884-6885.	6.6	11
206	Preparation of a thallium(I) diazotate. Structure, physicochemical characterization, and conversion to novel N-nitroso compounds. <i>Journal of the American Chemical Society</i> , 1988, 110, 2800-2806.	6.6	14
207	Rapid formation of a potent nitrosating agent by solvolysis of ionic nitrite in dichloromethane. <i>Journal of the Chemical Society Chemical Communications</i> , 1987, , 955.	2.0	24
208	Extent of DNA 2-hydroxyethylation by N-nitrosomethylethylamine and N-nitrosodiethylamine in vivo. <i>Carcinogenesis</i> , 1986, 7, 1335-1337.	1.3	14
209	Reduction of nitrosamines with aqueous titanium trichloride: convenient preparation of aliphatic hydrazines. <i>Journal of Organic Chemistry</i> , 1984, 49, 3470-3473.	1.7	43
210	Notes. Reductive destruction of hydrazines as an approach to hazard control. <i>Environmental Science & Technology</i> , 1983, 17, 240-243.	4.6	24
211	Safe disposal of carcinogenic nitrosamines. <i>Carcinogenesis</i> , 1983, 4, 315-319.	1.3	34
212	Carcinogenesis and aging. II. Modifying effect of aging on metabolism of methyl(acetoxymethyl)nitrosamine and its interaction with DNA of various tissues in rats. <i>Carcinogenesis</i> , 1983, 4, 967-973.	1.3	18
213	Deuterium isotope effect on metabolism of N-nitrosodimethylamine in vivo in rat. <i>Carcinogenesis</i> , 1983, 4, 821-825.	1.3	33
214	Stereochemistry of thialdine. <i>Journal of Heterocyclic Chemistry</i> , 1982, 19, 1301-1304.	1.4	8
215	Possible Mechanisms of Nitrosamine Formation in Pesticides. <i>ACS Symposium Series</i> , 1981, , 133-147.	0.5	0
216	Synthesis, analysis, and stability studies of ¹⁴ C-methyl(acetoxymethyl)nitrosamine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1981, 18, 1261-1272.	0.5	2

#	ARTICLE	IF	CITATIONS
217	N-nitrosothialdine. Synthesis, X-ray crystallography, and N-N rotational barrier. Tetrahedron, 1981, 37, 4143-4149.	1.0	16
218	Tritium gas exposure as an alternative to base-catalyzed exchange for the one-step tritiation of nitrosamines. Journal of Labelled Compounds and Radiopharmaceuticals, 1978, 14, 91-97.	0.5	1
219	Focal Suppression and Induction of Hyperplasia by the Bladder Carcinogens Butyl(4-hydroxybutyl)nitrosamine and Butyl(3-carboxypropyl)nitrosamine in Organ-Cultured Rat Bladder Epithelium. Journal of the National Cancer Institute, 1978, 60, 219-223.	3.0	0
220	Selective Induction of Intestinal Tumors in Rats by Methyl(acetoxymethyl)nitrosamine, an Ester of the Presumed Reactive Metabolite of Dimethylnitrosamine ² . Journal of the National Cancer Institute, 1977, 58, 1531-1535.	3.0	24
221	SYNTHESIS OF THE SELECTIVE BLADDER CARCINOGEN, N-(<i>n</i> -BUTYL)-N-(3-CARBOXYPROPYL)NITROSAMINE (BCPN). Organic Preparations and Procedures International, 1977, 9, 49-52.	0.6	3
222	Photochemical perturbation of Zâ€¢EE equilibria in nitrosamines. Journal of the Chemical Society Chemical Communications, 1976, , 633-634.	2.0	3
223	Reduction of Rat Liver Carcinogenicity of Î±-Nitrosomorpholine by a-Deuterium Substitution 2. Journal of the National Cancer Institute, 1976, 57, 1311-1313.	3.0	54
224	Spectral and other properties of some oxygenated derivatives of benzo[a]pyrene. Journal of Chemical & Engineering Data, 1973, 18, 332-334.	1.0	9
225	Deuterium Isotope Effect on the Carcinogenicity of Dimethylnitrosamine in Rat Liver 2. Journal of the National Cancer Institute, 1973, 51, 299-302.	3.0	80
226	Magnesium hydroxide as a thin-layer chromatographic adsorbent. Journal of Chromatography A, 1972, 69, 215-218.	1.8	7
227	Analysis of mixtures of isomeric polynuclear hydrocarbons by nuclear magnetic resonance spectrometry. Methylated derivatives of anthracene, benz[.alpha.]anthracene, benzo[c]phenanthrene, and pyrene. Analytical Chemistry, 1971, 43, 1411-1416.	3.2	8
228	Magnesium hydrogen as a thin-layer chromatographic adsorbent II. A unique system for separating polynuclear azaaromatic compounds. Journal of Chromatography A, 1970, 47, 20-26.	1.8	7
229	Facile hydrogen isotope exchange as evidence for an .alpha.-nitrosamino carbanion. Journal of the American Chemical Society, 1970, 92, 5747-5748.	6.6	50
230	Magnesium hydroxide as a thin-layer chromatographic adsorbent. Journal of Chromatography A, 1967, 31, 390-395.	1.8	8
231	Nuclear Magnetic Resonance Study of Oxiranes from Ephedrine Salts ^{1a} . Journal of Organic Chemistry, 1966, 31, 3921-3924.	1.7	38
232	Diazeniumdiolates (Formerly NONOates) in Cardiovascular Research and Potential Clinical Applications. , 0, , 431-446.		2